Literature DB >> 25214172

Is there a gender-related susceptibility for cisplatin ototoxicity?

Günay Kirkim1, Yüksel Olgun, Safiye Aktas, Müge Kiray, Efsun Kolatan, Zekiye Altun, Pınar Erçetin, Alper Bagriyanik, Osman Yilmaz, Hülya Ellidokuz.   

Abstract

Ototoxicity is a well-known side effect of cisplatin. Some genetic and non-genetic risk factors were described for cisplatin ototoxicity. Although there are some studies which point out a sex-related difference for cisplatin nephrotoxicity and neurotoxicity, sex-related differences for cisplatin ototoxicity have not been studied. The aim of this study is to reveal whether there is any gender-related difference for susceptibility to cisplatin ototoxicity in rats. Fourteen male, 14 female Wistar albino rats were divided into four groups; a female control, a male control, a female cisplatin and a male cisplatin group. Distortion Product Otoacoustic Emission and, Auditory Brainstem Response measurements were obtained. For the cisplatin groups 16 mg/kg of cisplatin was applied. On the 4th day audiological examinations were repeated. After killing, cochleae and brainstem tissues were evaluated by light and electron microscopy. The hearing of the female rat cisplatin group was found to have deteriorated more than the hearing of the male rat cisplatin group. Histopathological evaluation revealed more serious damage in the spiral ganglion and brainstem tissues of female rats. Hearing of female rats deteriorated more than the hearing of male rats upon application of cisplatin. This difference in hearing can be attributed to the more severe damage seen in neuronal tissues such as spiral ganglion cells and brainstem neurons.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25214172     DOI: 10.1007/s00405-014-3283-0

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  21 in total

1.  Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate.

Authors:  Won-Taek Choe; Nina Chinosornvatana; Kay W Chang
Journal:  Otol Neurotol       Date:  2004-11       Impact factor: 2.311

2.  Cisplatin-induced cytotoxicity in BSO-exposed renal proximal tubular epithelial cells: sex, age, and species.

Authors:  Yongke Lu; Akira Kawashima; Ikuo Horii; Laifu Zhong
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

3.  Differential gender differences in ischemic and nephrotoxic acute renal failure.

Authors:  Qingqing Wei; Mong-Heng Wang; Zheng Dong
Journal:  Am J Nephrol       Date:  2005-09-06       Impact factor: 3.754

4.  Cisplatin increases urinary sodium excretion in rats: gender-related differences.

Authors:  Donatas Stakisaitis; Giedre Dudeniene; Rimas Jonas Jankūnas; Grazina Grazeliene; Janina Didziapetriene; Birute Pundziene
Journal:  Medicina (Kaunas)       Date:  2010       Impact factor: 2.430

5.  Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats.

Authors:  Fatemeh Eshraghi-Jazi; Mehdi Nematbakhsh; Zahra Pezeshki; Hamid Nasri; Ardeshir Talebi; Tahereh Safari; Azam Mansouri; Safoora Mazaheri; Farzaneh Ashrafi
Journal:  Iran J Kidney Dis       Date:  2013-09       Impact factor: 0.892

6.  Evaluation of the effect of acetyl L-carnitine on experimental cisplatin ototoxicity and neurotoxicity.

Authors:  Dilek Gunes; Günay Kirkim; Efsun Kolatan; Enis Alpin Guneri; Candan Ozogul; Zekiye Altun; Bülent Serbetcioglu; Osman Yilmaz; Safiye Aktas; Kamer Mutafoglu; Ozlem Tufekci; Zübeyde Erbayraktar; Nur Olgun
Journal:  Chemotherapy       Date:  2011-04-27       Impact factor: 2.544

Review 7.  Framework for gender differences in human and animal toxicology.

Authors:  Michael Gochfeld
Journal:  Environ Res       Date:  2006-04-17       Impact factor: 6.498

8.  Ototoxicity from cisplatin therapy in childhood cancer.

Authors:  Patrícia P Coradini; Luciana Cigana; Simone G A Selistre; Letícia S Rosito; Algemir L Brunetto
Journal:  J Pediatr Hematol Oncol       Date:  2007-06       Impact factor: 1.289

Review 9.  Pharmacogenomics of sex difference in chemotherapeutic toxicity.

Authors:  Jeffrey Wang; Ying Huang
Journal:  Curr Drug Discov Technol       Date:  2007-06

10.  Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovarectomized rat model.

Authors:  Zahra Pezeshki; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Ali-Asghar Pilehvarian; Tahereh Safari; Fatemeh Eshraghi-Jazi; Maryam Haghighi; Farzaneh Ashrafi
Journal:  Toxicol Int       Date:  2013-01
View more
  9 in total

1.  Prophylactic etanercept treatment in cisplatin ototoxicity.

Authors:  Sinem Dasli; Murat Topdag; Ahmet Mutlu; Ahmet Kara; Murat Ozturk
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-20       Impact factor: 2.503

Review 2.  A Review of Cisplatin-Associated Ototoxicity.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Vikash Sewram
Journal:  Semin Hear       Date:  2019-04-26

3.  Age-corrected hearing loss after chemoradiation in cervical cancer patients.

Authors:  S Marnitz; L Schermeyer; S Dommerich; C Köhler; H Olze; V Budach; P Martus
Journal:  Strahlenther Onkol       Date:  2018-08-17       Impact factor: 3.621

4.  Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.

Authors:  T F Spracklen; A A Vorster; L Ramma; S Dalvie; R S Ramesar
Journal:  Pharmacogenomics J       Date:  2016-07-26       Impact factor: 3.550

5.  COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Authors:  Simon J Crabb; Karen Martin; Julia Abab; Ian Ratcliffe; Roger Thornton; Ben Lineton; Mary Ellis; Ronald Moody; Louise Stanton; Angeliki Galanopoulou; Tom Maishman; Thomas Geldart; Mike Bayne; Joe Davies; Carolynn Lamb; Sanjay Popat; Johnathan K Joffe; Chris Nutting; John Chester; Andrew Hartley; Gareth Thomas; Christian Ottensmeier; Robert Huddart; Emma King
Journal:  Eur J Cancer       Date:  2017-11-10       Impact factor: 9.162

Review 6.  Cisplatin-Associated Ototoxicity: A Review for the Health Professional.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Vikash Sewram
Journal:  J Toxicol       Date:  2016-12-27

Review 7.  Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds.

Authors:  Loredana G Marcu
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-20

8.  Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model.

Authors:  Hande Evin Eskicioğlu; Yüksel Olgun; Tekincan Çağrı Aktaş; Safiye Aktas; Efsun Kolatan; Efe Serinan; Zekiye Altun; Günay Kırkım; Osman Yılmaz; Nur Olgun
Journal:  J Int Adv Otol       Date:  2022-09       Impact factor: 1.316

9.  Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Birhanu T Ayele; Vikash Sewram
Journal:  BMC Cancer       Date:  2021-07-16       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.